7,404.50

+2.50

+0.03%

51,606.00

+221.00

+0.43%

26,927.50

-157.75

-0.58%

Russell 2000 Futures

2,778.80

+18.30

+0.66%

4.8590

+0.0220

+0.45%

25.64

-2.54

-9.01%

4,104.00

+29.10

+0.71%

73,736.97

-2,118.99

-2.79%

Crude Oil Dec 26

89.60

-1.23

-1.35%

US Private Equity

10,772.76

+11.83

+0.11%

NasdaqGS - Delayed Quote USD

Humacyte, Inc. (HUMAW)

0.0009 -0.0032 (-78.05%)

At close: August 25 at 3:59:50 PM EDT

Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights

Zacks 3mo ago

HUMAW
-78.05%
^GSPC

^DJI
Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know

Zacks 3mo ago

HUMAW
-78.05%
^GSPC

^DJI
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why

Zacks 6mo ago

HUMA

^GSPC

^DJI
RenovoRx, Inc. (RNXT) Reports Q3 Loss, Tops Revenue Estimates

Zacks 3d ago

RNXT

HUMA
Humacyte, Inc. (HUMA) Registers a Bigger Fall Than the Market: Important Facts to Note

Zacks 3d ago

HUMA

^GSPC

^DJI
Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Beats Revenue Estimates

Zacks 4d ago

DNTH

HUMA
Humacyte Innovative Research in Coronary Bypass and Vascular Regeneration to be Highlighted at American Heart Association Scientific Sessions 2026

GlobeNewswire 5d ago

HUMA
Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights

Zacks 9d ago

HUMA

^GSPC

^DJI
Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent Covering Symvess and Other Bioengineered Tissues

GlobeNewswire 11d ago

HUMA
Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner

GlobeNewswire 16d ago

HUMA
Why Humacyte, Inc. (HUMA) Outpaced the Stock Market Today

Zacks 18d ago

HUMA

^GSPC

^DJI
Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note

Zacks 20d ago

HUMA

^GSPC

^DJI

Mobilize your Website

View Site in Mobile | Classic

Share by: